thromboxane a2

Thromboxane A2, as an unstable intermediate between the prostaglandin endoperoxides and thromboxane B2, is a potent inducer of platelet aggregation and causes vasoconstriction.

Carbocyclic Thromboxane A2 can be used in related research in the field of life sciences. Its product number is T36548 and CAS number is 74034-56-3.

15(R)-Pinane thromboxane A2 is the (R)-epimer of pinane thromboxane A2 . 15(R)-PTA2 does not inhibit collagen-induced platelet aggregation (IC50s = 120-130 μM). It does not affect gastric tone in isolated rat gastric fundus when used at concentrations of 0.5 or 1.5 μg/ml and is less effective than PTA2 at inhibiting prostaglandin-induced contraction of isolated rat stomach muscle.

Cucumarioside A2-2 is a triterpene glycoside isolated from the Far-Eastern sea cucumber Cucumaria japonica, that exhibits antitumor activity.

Etodolac (AY-24236) inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. Etodolac is a pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.

Ketoprofen (RP-19583) is a propionic acid derivative and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. It inhibits cyclo-oxygenase I and II, decreasing the formation of prostaglandin and thromboxane precursors. This reduction in prostaglandin synthesis, mediated by prostaglandin synthase, is responsible for its therapeutic effects. Additionally, Ketoprofen decreases thromboxane A2 formation via thromboxane synthase, inhibiting platelet aggregation.

Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

Indobufen (Ibustrin) is an inhibitor of platelet aggregation and is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.

Ozagrel hydrochloride (OKY-046 HCl) is a selective thromboxane A(2) synthetase inhibitor used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

9-Oxononanoic Acid is an oxidized fatty acid, formed by the autoxidation of linoleic acid, which enhances phospholipase A2 (PLA2) activity and increases the production of thromboxane B2 in isolated human plasma.9-Oxononanoic Acid reduces hepatic neofatty acid synthesis and enhances the activity of rat hepatic carnitine palmitoyltransferase, a marker of β-oxidation. Activity.

Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.

RS-601 is a potent dual leukotriene D4/thromboxane A2 inhibitor that inhibits antigen-induced airway hyperresponsiveness (AHR) and shows asthmatic effects in a guinea pig model of asthma.

FUREGRELATE, a thromboxane A2 (TxA2) synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.

Imitrodast is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor for the treatment of immune system disorders, respiratory disorders, and cardiovascular diseases, and can be used in studies of arterial thrombosis, asthma, and coronary vasospasm.

Sulotroban potassium is a small molecule thromboxane A2 receptor (TXA2R) antagonist that can be used to study myocardial infarction and thrombosis.

Dazmegrel (UK 38,485) is a potent and specific thromboxane A2 (TXA2) synthase inhibitor for the prevention of increased whole platelet aggregation in normal pregnancy.

Daltroban (SKF 96148) is a specific thromboxane A2 (TXA2) receptor antagonist. Daltroban shows protective effect in reperfusion injury. Daltroban increase intracellular calcium in vascular smooth muscle cells.

Furegrelate sodium (U-63557A) is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium(U-63557A) inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.

NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

Porfimer sodium is t he sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm w

TPα and TPβ are two isoforms of the human TP receptor, the G protein-coupled receptor (GPCR) that mediates the actions of thromboxane A2 (TXA2). Although their distinct physiological functions have not been fully elucidated, TPβ is believed to be responsible for vascular endothelial growth factor-induced endothelial cell differentiation and migration whereas TPα appears to be the predominant isoform expressed in platelets. CAY10535 is a TP receptor antagonist that shows ~20-fold selectivity for TPβ (IC50 = 99 nM) relative to TPα (IC50 = 1,970 nM) in the inhibition of U46619-mediated Ca2+ mobilization. This compound exhibits relatively poor activity on platelets (IC50 = 985 nM) when inhibiting U-46619-induced platelet aggregation.

KP496 is a selective, dual antagonist for the Thromboxane A2 receptor (TP) and the Leukotriene D4 receptor (cysLT1).

FCE-27262 is a prostaglandin H2/thromboxane A2 receptor antagonist.

L 657925 is an antagonist of the thromboxane A2 receptor.

L-670,596 is a thromboxane A2/prostaglandin endoperoxide receptor antagonist.

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

(R)-(+)-Bay-K-8644 is a Ca2+ channel and dihydropyridine agonist that inhibits Ba2+ currents (IBa), induces central respiratory depression in cats, and inhibits platelet activation through competitive antagonism of thromboxane A2-prostaglandin H2 receptors.

TP receptor antagonist-1 (compound 7m) serves as an antagonist for the thromboxane A2 receptor (TP receptor), exhibiting IC50 values of 9.46 μM for TPa and 8.49 μM for TPb. It is utilized in the study of cardiovascular diseases [1].

TP Receptor Antagonist-2 (example 7n), a thromboxane A2 receptor (TP receptor) antagonist, exhibits inhibitory activity with IC50 values of 5.64 μM for TPα and 5.27 μM for TPβ. It effectively inhibits platelet aggregation [1].

IS-145 is a thromboxane A2 receptor antagonist.

Etersalate inhibits platelet function. It also reduces thromboxane A2 (TXA2) levels.

Indobufen sodium is a Thromboxane A2 antagonist and Cyclooxygenase inhibitor.

Nafagrel is a thromboxane A2 synthetase inhibitor.

I-BOP is an agonist (KD=0.61 nM) at the thromboxane A2 receptor (TP). I-BOP promotes cell proliferation by activating the PI3K pathway in vascular smooth muscle.

Nizofenone, a thromboxane A2 (TXA2) biosynthesis inhibitor, is used as a neuroprotective drug and used to treat stroke.

LCB-2853 is a potent thromboxane A2 prostaglandin H2 (TXA2 PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.

Pentifylline is a vasodilator that inhibits platelet aggregation and thromboxane A2 synthesis, decrease the release of free radicals, and may be neuroprotective [1].

Nafagrel hydrochloride is a thromboxane A2 synthetase inhibitor.

HN-11501 is a Thromboxane A2 receptor antagonist.

Ici D1542 is a drug that exhibits both potent, selective TXS inhibition and TXA2 receptor antagonism. Ici D1542 is an effective thromboxane A2 synthase inhibitor and receptor antagonist in vitro.

CV 6504 is a dual inhibitor of thromboxane A2 synthetase and 5-lipoxygenase. It also possesses oxygen scavenging activity.

KW 4099 is a thromboxane A2 antagonist.

ICI 192605 is a potent thromboxane A2 receptor (TP receptor) antagonist.

SQ 26655 is an antagonist of thromboxane A2/prostaglandin H2.

Z-335 Salt, a thromboxane A2 receptor antagonist, is used potentially for the treatment of arterial occlusive disease.

Ifetroban (BMS-180291) sodium is an orally active thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) receptor antagonist used to study myocardial ischemia, stroke, hypertension, thrombosis, and cardiomyopathy.